V-ICI. Annual Report 2004

Size: px
Start display at page:

Download "V-ICI. Annual Report 2004"

Transcription

1 V-ICI VUmc Institute for Cancer & Immunology Annual Report 2004 Address VUmc Institute for Cancer & Immunology De Boelelaan HV Amsterdam The Netherlands phone: (31) fax: (31) website : 1

2 2

3 Contents 1. Introduction Awards and honours 7 2. Organization of the institute 9 3. Input and output data Scientific staff Publications Full international papers Local papers Books Proceedings Other publications Letters to the editor Reports Theses Evaluation of input and output data Summary of research staff input Output data Evaluation of peer-reviewed publications Summary input and output Research programmes & indicators of esteem Research programmes Program 1: Oncogenesis Program 2: Immunopathogenesis Program 3: Disease profiling Program 4: Therapy Indications of esteem Organized (inter)national meetings and courses International collaboration International guests Memberships of editorial boards (Inter)national functions Lectures Grants Grants obtained in Scientific Committee Scientific committee clinical protocols Scientific committee DEC protocols Education Graduate profile Master oncology PhD program 134 3

4 4

5 1. Introduction This is the second annual report of the research institute V-ICI (VUMC Institute for Cancer and Immunology). V-ICI is one of the 5 research institutes of the VU University Medical Center (VUMC). V-ICI has been founded on January 1, 2003 by merging two separate institutes: OOVU, the Onderzoeksinstituut voor Oncologie VU and I&O, the research institute for Immunologie en Ontsteking. V-ICI was created to integrate all research efforts in oncology and immunology in such a way that they strengthen themselves to reach well-defined, interconnected goals. V-ICI is positioned horizontally in the structure of the VUMC, thus interfacing with the different clusters of clinical and pre-clinical departments. V-ICI reports directly to the Board of Directors of the VUMC, in accordance with the Management Regulations VUMC (June 1, 2002) by means of: a long-term research program a scientific annual report quality control of the research, training and supervision of graduate students consultancy about tasks of staff members The V-ICI organization is built around the top researchers in oncology and immunology in the VUMC. They are the members of the executive board, advising the management board that heads the institute. A detailed description of the organization of V-ICI, together with the organization scheme is given in chapter 2. The mission of V-ICI The mission of V-ICI is to coordinate, stimulate and facilitate: top level fundamental, translational and patient-related research in immunology and cancer, within the framework of a defined number of research programs training of young investigators to achieve excellence in fundamental and clinical research To this end the tasks of V-ICI are: facilitation and coordination of scientific oncology and immunology research quality control and stimulation of research conducted in joint departments, research groups and clusters development of long-term research strategies attuning the institutional policy and the policies of the participating (heads of) departments training, supervision and assessment of graduate students within the institute organization of courses, national and international seminars, entrance examinations, publications, conferences and other activities that are relevant for achieving the above goals The programs of V-ICI The former OOVU and I&O research programs are integrated in 4 comprehensive V-ICI programs, which are closely interconnected to produce clinically useful tools. The four programs are: 1. Oncogenesis - Viral oncogenesis - Cancer genomics - Genetic predisposition 2. Immunopathogenesis - Homeostasis control - Inflammation - Host-pathogen interaction - Tumor immunology and pre-clinical immune therapy 3. Disease profiling - Solid tumors - Hematological malignancies - Chronic inflammatory diseases 5

6 4. Therapy - Chemotherapy - Immune therapy - Radiotherapy and surgery - Gene therapy - Quality of life V-ICI in 5 years V-ICI aims, on the basis of fundamental research in programs 1 and 2, to introduce and evaluate new techniques and strategies to profile and treat both immunological and malignant diseases (program 3 and 4). In particular V-ICI will focus on: Virus-induced oncogenesis and the role of cancer genes in frequently occurring sporadic and inherited tumors Development of cell based immunotherapy against cancer and new immunosuppressive methods in immunological diseases Classification of diseases and disease monitoring by molecular imaging and genomics Introduction and evaluation of new therapeutic modalities, combining immunotherapeutical approaches, DNA technology and improving existing therapy methods Through the concerted efforts of the 4 programs with help by frequent program meetings and the monthly organised V-ICI evening lectures these aims are well within reach of V-ICI. These aims of V-ICI will greatly be facilitated by the Cancer Center Amsterdam (CCA). CCA was founded in 2003 to facilitate all clinical activities in the VUMC regarding cancer patients and to raise funds for V-ICI research. V-ICI and CCA work closely together, the V-ICI director being vice-director of the CCA. The cooperation will enable to speed up clinical translation of fundamental and early clinical research. CCA already raised funds, to establish a 4000 m 2 research building for V-ICI research, incorporating a GMP facility for the preparation of stem cells, cancer cell vaccines as well as gene and immunotherapy products, and a GLP facility for analysis of drugs and molecular characteristics of tumors and patients. Furthermore, existing facilities like microarray and cyclotron, as well as the (research) laboratories in the VUMC with their quality accreditations, greatly enhance V-ICI research. Careful selection of new projects, together with personnel, will be the main instrument to reinforce the 4 programs in the future and to diminish less promising, smaller research efforts still existing. Analysis, perspectives and expectations for the institute V-ICI is facing several important challenges. First of all, it is a merged institute that is only one year in effective existence. It has been instituted to improve on the already excellent input/output figures of the original two institutes (OOVU and I&O). The enthusiasm and professionalism with which the merge has been undertaken is impressive. Four programs have been formed and most importantly, the eagerness to formulate ways to make them more and more comprehensive, that is especially by selecting new projects and their PhD students on their quality and their capacity to strengthen the programs, is great. Meanwhile, formulating programs is one thing, but not earlier than in four years it will be clear whether V-ICI has succeeded in this regard. Another major challenge is to create bench to bed research lines through the four programs. Some of these are already in progress, like the research on HPV in cervix carcinoma in program 1 and 2, interconnected with profiling in program 3 and therapeutic strategies in program 4, and DC vaccination research lines in program 2 and 4, but more of these lines have to be instituted to make research activities more and more translational. A third challenge is to integrate research groups up to now involved in infectious diseases to make them more effective in the projects and programs on developing immunological and immunosuppressive therapies. Also, this will take some years, as it will be mostly done by careful selection of new projects and PhD students. 6

7 The fourth challenge is to make program 4 more comprehensive. Although cancer and immunological diseases require all kinds of therapeutical approaches, research efforts require more focussing, while maintaining the strong parts. It will be a major point of forthcoming discussions. Another challenge, steadily becoming more and more of utmost importance, is to look for possibilities to create large cooperative research groups with partners outside VUMC. As politics, financial support, complicated technology and the demand for ever-increasing patient numbers request, the University Medical Centers in the Western part of the Netherlands have a need for intensive collaboration. V-ICI, within the VUMC framework, will take its responsibility and will help to create such networks. Much already has been done in this regard, still more is needed. V-ICI is based on a strong fundament of departments interested in "translational research" in particular the departments of Pathology, Otolaryngology/Head-Neck-Surgery, Clinical Genetics and Human Genetics, Molecular Cell Biology and Immunology, Nuclear Medicine, Rheumatology, Hematology, Medical Oncology and Radiotherapy. All of these are active in bench to bedside research and collaborate intensively. In- and output data are listed in detail in chapter 3. The efforts of these and all departments of V-ICI, within the 4 programs, are greatly supported by the Cancer Center Amsterdam (CCA), founded to facilitate cancer research and to stimulate and support comprehensive care in the VUMC for patients with cancer by attracting financial resources form various sponsors. The CCA has already collected around 20 million euros to built a 4000 m 2 research building in 2005, and to acquire such innovative technology as a PET-CT scan and an FT-MS for proteomics research. Cancer research without an extensive educational program will not last long. Therefore, V-ICI is heavily involved in educating programs aimed at the training of undergraduate students, both medical and biomedical, graduate (PhD) students and postdocs. This program consists of theoretical and practical courses in which our senior staff is actively participating. For medical students V-ICI organizes both an Oncology and an Immunology graduation profile. Furthermore, for the top medical students V-ICI is providing TOP-masterclasses in Oncology and Immunology as well as in the General Master Biomedical Sciences, differentiation Immunology. For biomedical students V-ICI participates in the TOP-master in Oncology program, which is aimed at the training of students for a research function in an oncological research institute. The foresights are so excellent to acquire young students to attain PhD positions in the future. See inmore detail Chapter 6. PhD students in V-ICI follow various theoretical and practical courses, most of them organized by the graduate institutes, such as Oncology Graduate Institute Amsterdam (OOA) and Amsterdam Leiden Institute for Immunology (ALIFI), that V-ICI participates in. Monthly V-ICI lectures are organized in which the program/project leaders of the 4 programs of V-ICI are actively involved. These lectures are aimed at achieving more integration of the research performed in the 4 different programs and for education purposes for researchers in V-ICI Awards and honours In July 2004 H. Moed (Dermatology) received 3 travel grants for The International Congress of Immunology: 1. Federation of Clinical Immunology Societies (FOCIS) American travel award (623 euro); 2. European Federation of Immunological Societies (EPIS), European travel award (375 euro); 3. Nederlands Vereniging voor Immunologie (NVVI), Nederlandse reisbeurs (250 euro) Mohammad Zareie (Molecular Celbiology and Immunology) won the best poster award at the combined meeting of the International Society of Peritoneal Dialysis and EuroPD (August 28-31, 2004) on a poster entitled : PD fluid-injuced changes of the peritoneal membrane are largely revesible. The selected abstract for oral presentation and travel award EMDS-meeting (October 14-16, 2004) was won by Gerben van der Bij (Surgery): Role of macrophages in the prevention of liver metastasis. TBH Geijtenbeek (Molecular Celbiology and Immunology) received the EMDS Travel award and the BD Biosciences Award of the European Macrophage and Dendritic Cell Society (Barcelona, October 15, 2004) 7

8 On November 11, 2004 in Berlin, C.A. Uyl-de Groot et al. (Nuclear Medicine) received the EANM Springer award for best clinical paper T.D. de Gruijl (Medical Oncology) received the Prostate Cancer Foundation Research Award ($ 100,000). J. de Vries-Bouwstra (Rheumatology) won the Abbott Award in clinical practice on behalf on the Best investigators, EULAR 2004, Berlin. V.P. van Halm (Rheumatology) received the Young Investigators Abbott Award at the Najaarsdagen NVR 2004, Veldhoven. The Abbott ACR Award was won by I.E.M. Bultink (Rheumatology), ACR 2004, San Antonio. 8

9 2. Organization of the VUMC Institute for Cancer and Immunology Board VUmc Advisory Council Program 1 Oncogenesis Management Board Education Committee Program 2 Immunopathogenesis Executive Board Program 3 Disease profiling Plenary Meeting Program 4 Therapy Scientific Research Committee Staff Management Board One director and two deputy directors constitute the Management Board of V-ICI. Two policy-makers and a secretary of V-ICI assist him. The deputy directors replace the director in his absence and assist him in the execution of his tasks. The Management Board meets every fortnight. Management Board (MB) members: Prof.dr. P.C. Huijgens, director Prof.dr. G. Kraal, vice director Dr. W.R. Gerritsen, vice director Staff Dr. P. Keblusek, management Dr. M.A. van der Pol (from ), management Y. Duiker, secretary Advisory Council The Advisory council of V-ICI is composed of 5 to 9 members, two to four of them from outside the VUMC. The members of the Advisory Council are appointed by the VUMC Board of Directors. The Board of Directors selects the members upon recommendation of the management board of V-ICI and after having consulted the heads of departments participating in V-ICI. The council advises V-ICI about its strategic policy. The Advisory Council meets at least every 6 months. Advisory Council members: Prof.dr. C.R. Leemans, chairman Prof.dr. M.A. Blankenstein Prof.dr. B.A.C. Dijkmans Prof.dr. C.D. Dijkstra Prof.dr. G. Giaccone 9

10 Prof.dr. C.J.L.M. Meijer Prof.dr. B.J. Slotman 2 external vacancies Education Committee The education committee advises about the organization and quality of graduate students training and supervises the progress of the graduate research performed by V-ICI graduate students. More in detail the education committee, by means of subgroups, organizes and advises about training in the framework of the: - oncology profile - immunology profile - masters education in oncology - masters education in immunology - graduate students education Each of these five subgroups are composed of the main teachers within the education involved. Every subgroup delegates one coordinator to the education committee. The education committee gives asked and unasked advice about the quality and quality maintenance of education within V-ICI. The education committee meets at least three times a year. Education committee (CO) members: Prof.dr. R.H.J. Beelen, chairman Dr. P. Keblusek, secretary Prof.dr. Y. van Kooyk Dr. R.E. Mebius Prof.dr. G.A. Meijer Subgroups: Oncology profile committee members: Dr. P. Keblusek, profile coordinator Dr. B.J.M. Braakhuis Dr. A.A. van de Loosdrecht Prof.dr. G.A. Meijer Dr. E.H. Smorenburg Immunology profile committee members: Dr. P. Keblusek, profile coordinator (till ) Dr. M.A. van der Pol, profile coordinator (from ) Dr. B.J. Appelmelk Dr. B.M.E. von Blomberg Dr. T.D. de Gruijl Dr. I. van der Horst Prof.dr. Y. van Kooyk Prof.dr. G. Kraal Coordinator of the Master Oncology Dr. J. van Denderen Board of examiners Master Oncology Prof.dr. G.J. Peters, chairman Prof.dr. R.H. Beelen, vice chairman Prof.dr. R.J. Scheper Dr. J. van Denderen, secretary Coordinator of the Master Immunology Prof.dr. Y. van Kooyk Board of examiners Master Immunology (part of Master Biomedical Science) Prof.dr. B. Oudega, chairman Prof.dr. R.H. Beelen, vice chairman 10

11 Dr. B.M. Bakker Dr. K.S. Kits, secretary Directorate OOA Prof.dr. C.J.L.M. Meijer (VUmc-V-ICI), chairman Prof.dr. J.J. Neefjes (NKI) Prof.dr. R.P.J. Oude Elfering (AMC) Dr. P. Keblusek/Dr. M.A. van der Pol (from ) (VUmc-V-ICI) M.K. van der Velde (NKI) Dr. Y.E. Donselaar (AMC) ALIFI PhD committee Dr. R.E. Mebius (VUmc-V-ICI) Dr. H. Schuytemaker (CLB) Dr. R. van Lier (AMC) SMBWO committee (Netherlands Foundation for Medical-Biological Research) Dr. F. Arwert Prof.dr. C.D. Dijkstra Dr. P.H.M. Savelkoul Prof.dr. R.J. Scheper Prof.dr. C.M.J.E. Vandenbroucke-Grauls Executive Board The program leaders constitute the Executive Board (EB), chaired by the director of V-ICI. The EB meets every 2 months. The EB advises the Management Board about: - research projects - long-term policy with respect to personnel and materials - first money stream graduate students - allocation of equipment of > euro - all matters concerning V-ICI, whether on request or not Executive Board (EB) members: Program 1: Oncogenesis Dr. R.H. Brakenhoff Dr. P.J.F. Snijders Prof.dr. H. Joenje Program 2: Immunophathogenesis Prof.dr. Y. van Kooyk Prof.dr. R.H.J. Beelen Dr. E. Hooijberg Program 3: Disease profiling Prof.dr. G.A. Meijer Prof.dr. G.A.M.S. van Dongen Dr. O.S. Hoekstra Prof.dr. C.L. Verweij Program 4: Therapy Prof.dr. G.J. Ossenkoppele Prof.dr. S. Senan Prof.dr. B.A.C. Dijkmans Prof.dr. G.J. Peters Plenary Meeting The heads of the departments participating in V-ICI and other persons involved meet once a year during the Plenary Meeting. This meeting advises the Management Board whether on request or not about all matters concerning V-ICI. Fixed agenda points are: i. long-term policy V-ICI, ii. annual report and iii. Management Board policy and Executive Board policy. 11

12 Heads of the departments involved in V-ICI: Prof.dr. M.A. Blankenstein - Clinical chemistry Prof.dr. S.A. Danner Internal medicine Prof.dr. B.A.C. Dijkmans - Rheumatology Prof.dr. C.D. Dijkstra - Molecular Celbiology and Immunology Prof.dr. H.P. van Geijn - Obstetrics and Gynaecology Prof.dr. G. Giaccone - Medical Oncology Prof.dr. H.J.Th.M. Haarman - Surgery Prof.dr. J.J. Heimans - Neurology Prof.dr. P.C. Huijgens Haematology Prof.dr. L.P. ten Kate - Clinical genetics and antropogenetics Prof.dr. J.J. de Lange - Anesthesiology Prof.dr. A.A. Lammertsma - Nuclear Medicine Prof.dr. C.R. Leemans Otolaryngology/Head and Neck Surgery Prof.dr. R.A. Manoliu - Radiology Prof.dr. C.J.L.M. Meijer Pathology Prof.dr. C.J.J. Mulder Gastro-enterology and hepatology Prof.dr. P.E. Postmus - Pulmonology Prof.dr. J.A. Rauwerda - Urology Prof.dr. P.J. Ringens - Ophthalmonoly Prof.dr. J.J. Roord - Paediatrics Prof.dr. B.J. Slotman - Radiotherapy Prof.dr. Th.M. Starink - Dermatology Prof.dr. C.M.J.E. Vandenbroucke-Grauls - Medical Microbiology and Infection control Prof.dr. H.M. van der Ploeg - Medical Psychology Prof.dr. W.P. Vandertop - Neurosurgery Prof.dr. I. Van der Waal - Oral and Maxillofacial Surgery and Pathology Prof.dr. P.IJ.M. Wuisman - Orthopaedics Scientific Research Committee (CWO) The V-ICI CWO gives asked and unasked advice to the MB about the research policy and about the feasibility of new research projects. The CWO advises specifically about the quality and the feasibility of all research proposals that need permission of the ethical committees for patient related or animal related research before they can be realized. The CWO is divided into a council that treats merely animal related protocols and a council that treats patient related protocols and other project proposals. Research proposals made on behalf of (inter) nationally recognized joint ventures (EORTC, HOVON, SIOP, SKION) and multi-center studies in which the VUMC is not the main judging committee, are judged only marginally on local feasibility. The CWO meets twice a month. Scientific Research Committee (CWO) members: Dr. G.J.L. Kaspers, chairman Dr. M.A. van Agtmael Dr. J. van den Born Prof.dr. E. Bloemena Dr. A.A. van Bodegraven Prof.dr. E. van Boven Dr. B.J.M. Braakhuis Dr. P. Keblusek/Dr. M.A. van der Pol (from ), secretary Dr. F.A.E. Kruyt Dr. A.A. van der Loosdrecht Dr. T.J. Stoof Dr. B. Wilhelm Dr. B. van Triest CWO (Animal Experiments Committee) members: Prof.dr. R.J. Scheper, chairman Prof.dr. G. Kraal Dr. T. van der Berg Dr. V. van Beusechem Dr. P. Keblusek/Dr M.A. van der Pol (from ), secretary 12

13 3. Input and output data 3.1. Scientific staff Abbreviations: ANES: Anesthesiology DERM: Dermatology GE: Gastry-enterology and Hepatology HEMA: Haematology HLK: Surgery IG: Internal Medicine KC: Clinical Chemistry KG: Paediatrics KGA: Clinical Genetics and Antropogenetics KNO: Otolaryngology/Head and Neck Surgery LONG: Pulmonology MCBI: Molecular Celbiology and Immunology MMI: Medical Microbiology and Infection control MPSY: Medical Psychology MZKC: Oral and Maxillofacial Surgery and Pathology NCH: Neurosurgery NEU: Neurology NUCL: Nuclear Medicine ONC: Medical Oncology OOG: Ophthalmonoly ORTH: Orthopaedics PA: Pathology RAD: Radiology REU: Rheumatology RTH: Radiotherapy URO: Urology V&G: Obstetrics and Gynaecology Program 1: Oncogenesis Dept WP Fte Full prof Prof.dr. M.A. Blankenstein KC 1 0,05 Prof.dr. H. Joenje KGA 1 1,00 Prof.dr. Ch.R. Leemans KNO 1 0,05 Prof.dr. R.H.J. Beelen MCBI 1 0,30 Prof.dr. I van der Waal MHK 1 0,15 Prof.dr. C.J.L.M. Meijer PA 1 0,12 Prof.dr. J. Middeldorp PA 4 0,40 Prof.dr. P. Kenemans V&G 1 0,05 Prof.dr. R.H.M. Verheijen V&G 1 0,05 Associated prof Dr. F. Arwert KGA 1 0,70 Dr. R.H. Brakenhoff KNO 1 0,60 Assistent prof Dr. C.B.M. Oudejans KC 1 0,30 Dr. F. Menko KGA 1 0,10 Dr. G. Pals KGA 1 0,10 Dr. B.J.M. Braakhuis KNO 1 0,60 Dr. F.J. Kemenade PA 1 0,10 Dr. J.J. Oudejans PA 4 0,20 Dr. M.M.C.G. Bleeker PA 2 0,80 Dr. P.J.F. Snijders PA 1 0,60 Dr. J. Dorsman V&G 1 0,30 Total tenured staff 6,57 13

14 Dept WP Fte Non tenured staff Dr. P.A. van der Pol HEMA 4 0,75 Dr. A. Medhurst KGA 3 1,00 Dr. H. van der Vrugt KGA 3 0,75 Dr. J. de Winter KGA 1 / 2 1,00 Dr. P.K.E. Börjesson KNO 1 0,10 Drs. D.J. Kuik KNO 3 0,10 Dr. A. Greijer ONC 4 1,00 Dr. B. Carvalho PA 3 1,00 Dr. D.A.M. Heideman PA 3 / 4 0,75 Dr. F.M. Raaphorst PA 3 0,50 Dr. R.D.M. Steenbergen PA 2 0,80 Dr. S.J.C. Stevens PA 4 0,40 Dr. T.G.M. Lauterslager PA 3 0,40 PhD students Drs. S. Ouburg GE 1 0,37 Drs. E. Blom KGA 1 0,60 Drs. F. Léveillé KGA 3 0,50 Drs. M. Levitus KGA 1 0,60 Drs. N. Ameziane KGA 2 0,20 Drs. H.J.T. Zeeburg KNO 3 0,75 Drs. M P. Tabor KNO 1 0,10 Drs. S.J. Smeets KNO 1 0,75 Drs. J.F. Bremmer MHK 1 0,75 Drs. J. de Wilde PA 1 0,75 Drs. J. van Beek PA 3 0,20 Drs. J. van Galen PA 3 1,00 Drs. N. Bulkmans PA 2 0,75 Drs. S. Bulk PA 2 0,75 Drs. S.A.G.M. Cillessen PA 3 0,75 Drs. B. Hermsen V&G 4 0,75 Total non tenured staff 18,12 Total research staff 24,69 Program 2 : Immunopathogenesis Full prof Dept WP Fte Prof.dr. D.P. Bruynzeel DERM 1 0,30 Prof.dr. A.S. Peña GE 1 0,40 Prof.dr. C. Dijkstra MCBI 1 0,05 Prof.dr. C.L. Verweij MCBI 1 0,30 Prof.dr. G. Kraal MCBI 1 0,60 Prof.dr. R.H.J. Beelen MCBI 1 0,30 Prof.dr. Y. van Kooyk MCBI 1 0,70 Prof.dr. C.M.J.E. Vandenbroucke-Grauls MMI 1 0,20 Prof.dr. R.J. Scheper PA 1 0,40 Prof.dr. B.A.C. Dijkmans REU 1 0,01 Associated prof Dr. B.J. Appelmelk MMI 1 0,70 14

15 Dr. W. Bitter MMI 1 0,70 Dr. W.R. Gerritsen ONC 1 0,20 Assistent prof Dr. E.M. de Boer DERM 1 0,10 Dr. S. Gibbs DERM 1 0,80 Dr. T. Rustemeijer DERM 1 0,30 Dr. T.J. Stoof DERM 1 0,10 Dr. J.B.A. Crusius GE 1 0,40 Dr. J. van der Sijp HLK 1 0,35 Dr. M.A. van Agtmael IG 1 0,30 Dr. E.W.A. Kamperdijk MCBI 1 0,10 Dr. I.M. van Die MCBI 1 0,60 Dr. J. van den Born MCBI 1 0,80 Dr. N. van Rooijen MCBI 1 0,80 Dr. R.E. Mebius MCBI 1 0,80 Dr. T. van den Berg MCBI 1 0,60 Dr. T.B.H. Geijtenbeek MCBI 2 1,00 Dr. W. van Dijk MCBI 1 0,70 Dr. I. Simoons-Smit MMI 1 0,10 Dr. P.H.M. Savelkoul MMI 1 0,10 Dr. A.J.M. van den Eertwegh ONC 1 0,25 Dr. E. Hooijberg PA 1 0,50 Dr. M.B.E. von Blomberg PA 1 0,40 Other tenured staff Drs. G. Kirtschig DERM 1 0,10 Drs. S. Zweegman HEMA 1 0,50 Total tenured staff 14,56 Dept WP Fte Non tenured staff Dr. R. Spiewak DERM 3 1,00 Dr. M. van Egmond HLK 1 0,75 Dr. P. Zwijnenburg KG 1 0,20 Dr. A. Lekkerkerker MCBI 2 1,00 Dr. A.J. Engering MCBI 2 0,50 Dr. C.A. Aarnoudse MCBI 3 1,00 Dr. C.D. Richters MCBI 3 0,20 Dr. C.H. Grün MCBI 2 1,00 Dr. E. Saeland MCBI 3 1,00 Dr. I. Arce MCBI 2 1,00 Dr. J. den Haan MCBI 2 0,80 Dr. J.G.I. van Rietschoten MCBI 2 1,00 Dr. J.N. Samsom MCBI 3 1,00 Dr. M. van Egmond MCBI 1 0,25 Dr. M. Zareire MCBI 3 0,75 Dr. R.J.A. Fijneman MCBI 3 0,70 Dr. S.I. Gringhuis MCBI 1 0,80 Dr. A.M. van der Sar MMI 4 0,70 Dr. M. Lllamas MMI 3 1,00 Dr. J.J. van der Vliet ONC 3 0,70 Dr. W. Kölgen ONC 4 0,56 15

16 Dr. H. Bontkes PA 3 1,00 Dr. M. Schreurs PA 3 1,00 Dr. T.G.M. Lauterslager PA 3 0,30 PhD students Drs. H. Moed DERM 1 0,56 Drs. M. Toebak DERM 1 0,75 Drs. H. Fidder GE 1 0,75 Drs. J. Spaargaren GE 1 0,75 Drs. J.M. Lyons GE 1 0,75 Drs. K. Lammers GE 1 0,37 Drs. S. Ouburg GE 1 0,37 Drs. G. van der Bij HLK 1 0,75 Drs. S.J. Oosterling HLK 3 0,75 Drs. G.Th.J. van Well KG 1 0,20 Drs. A.P.J. van der Marel MCBI 1 0,75 Drs. C.G. Timmer MCBI 1 0,75 Drs. E.A. Koppel MCBI 2 0,75 Drs. I.S. Ludwig MCBI 3 0,75 Drs. J. Dunnen MCBI 2 0,20 Drs. J.J. Garcia-Vallejo MCBI 1 0,50 Drs. J.W.A.M. Celie MCBI 1 0,75 Drs. K.P.J.M. van Gisbergen MCBI 2 0,75 Drs. L. Witte MCBI 3 0,75 Drs. L.C. Paessens MCBI 2 0,75 Drs. M. Otten MCBI 2 0,75 Drs. M.F.R. Vondenhoff MCBI 2 0,75 Drs. P.A.G. Liempt MCBI 3 0,75 Drs. S. Oosterling MCBI 1 0,25 Drs. S. van der Vliet MCBI 1 0,75 Drs. W.W.J. Unger MCBI 3 0,10 Drs. A. Abdallah MMI 1 0,70 Drs. A. Rijsmus MMI 1 0,75 Drs. G. Blaauw MMI 1 0,40 Drs. A.M.E. Bruynzeel ONC 3 0,75 Drs. K.B.J. Scholten PA 2 0,75 Drs. R. van de Ven PA 3 0,75 Drs. S. Santegoets PA 3 0,75 Drs. M. Moreno V&G 1 0,75 Total non tenured staff 40,61 Total research staff 55,17 Program 3: Disease profiling Dept WP Fte Full prof Prof.dr. A.S. Peña GE 1 0,40 Prof.dr. P.C. Huijgens HEMA 1 0,10 Prof.dr. S. Meijer HLK 1 0,20 Prof.dr. Ch.R. Leemans KNO 1 0,05 Prof.dr. G.A.M.S. van Dongen KNO 1 0,60 Prof.dr. P.E. Postmus LONG 1 Pm 16

17 Prof.dr. C. Dijkstra MCBI 1 0,05 Prof.dr. C.L. Verweij MCBI 1 0,50 Prof.dr. I. van der Waal MHK 1 0,15 Prof.dr. C.M.J.E. Vandenbroucke-Grauls MMI 1 0,10 Prof.dr. G.J. Teule NUCL/PET 1 0,07 Prof.dr. A.A. Lammertsma NUCL/PET/KFI 1 0,15 Prof.dr. C.J.L.M. Meijer PA 1 0,03 Prof.dr. P. van der Valk PA 1 0,10 Prof.dr. J. Castelijns RAD 1 0,10 Prof.dr. B.A.C. Dijkmans REU 1 0,07 Prof.dr. P. Kenemans V&G 1 0,05 Prof.dr. R.H.M. Verheijen V&G 1 0,10 Assistant prof Dr. J.B.A. Crusius GE 1 0,40 Dr. S.A. Morré GE 1 0,80 Dr. R.P.H. Peters IG 1 0,50 Dr. A.Y.N. Schouten-van Meeteren KG 1 0,30 Dr. E.F. Smit LONG 1 0,20 Dr. P.W.A. Kunst LONG 1 0,10 Dr. T.G. Sutedja LONG 1 0,10 Dr. C.T.M. van der Pouw-Kraan MCBI 1 0,90 Dr. E. van der Vorm MMI 1 0,10 Dr. P.H.M. Savelkoul MMI 1 0,20 Dr. A.D. Windhorst NUCL/PET 1 0,20 Dr. E.F.I. Comans NUCL/PET 1 0,20 Dr. E.W. van Tilburg NUCL/PET 1 1,00 Dr. G.W.M. Visser NUCL/PET 1 0,30 Dr. H.J. Pijpers NUCL/PET 1 0,15 Dr. J.D.M. Herscheid NUCL/PET 1 0,20 Dr. R. Boellaard NUCL/PET/FMT 1 0,15 Dr. O.S. Hoekstra NUCL/PET/Keb 1 0,50 Dr. G.A. Meijer PA 4 0,20 Dr. J.A.M. Belien PA 1 0,50 Dr. P.J.F. Snijders PA 1 0,40 Dr. A.E. Voskuyl REU 1 0,05 Dr. D. van Schaardenburg REU 1 0,10 Dr. I.E. van der Horst-Bruinsma REU 1 0,40 Dr. W.F. Lems REU 1 0,13 Dr. A.A. Verstraeten V&G 1 0,30 Dr. J. Dorsman V&G 1 0,50 Other tenured staff Drs. J. Zijlstra-Baalbergen HEMA 1 0,50 Drs. J.J.M. van der Hoeven NUCL/PET 1 Pm Drs. L. Hooft NUCL/PET/Keb 1 0,10 Dr. A. van Kuyk REU 1 Pm Dr. C.J. van der Laken REU 1 Pm Dr. I. Bultink REU 1 Pm Dr. M. Nielen REU 1 Pm Dr. M. van der Paardt REU 1 Pm Dr. M. van Rossum REU 1 Pm Total tenured staff 12,3 17

18 Dept WP Fte Not tenured staff Dr. G.E. Baltus MCBI 2 1,00 Dr. T. Hooper-Van Veen MCBI 3 0,10 Dr. C.F.M. Molthoff NUCL/PET 1 0,40 Dr. S.J.C. Stevens PA 4 0,30 PhD students Drs. H. Fabry HLK 1 0,20 Drs. R.C.J. de Jonge KG 1 0,20 Drs. B.M. Tijink KNO 3 0,55 Drs. D.J. Kuik KNO 4 0,10 Drs. D.R. Colnot KNO 1 0,10 Ir. L.R. Perk KNO 2 0,75 Drs. A. Pasic LONG 3 1,00 Drs. B. Witgen LONG 3 1,00 Drs. G.J.M. Herder LONG 1 0,20 Drs. R. van den Berg LONG 2 1,00 Drs. E.G.M. Baarsen MCBI 1 0,75 Drs. P.V. Kasperkovic MCBI 1 0,75 Drs. M. Mooij MMI 1 0,70 Drs. A.A.M. van der Veldt NUCL/PET 1 0,20 Drs. C.J. Hoekstra NUCL/PET 1 0,04 Drs. J. Emmering NUCL/PET 1 0,50 Drs. U. Joshi NUCL/PET 1 0,30 Drs. W.G.E. Direcks NUCL/PET 3 0,75 Dr. J.J.F. Muris PA 3 1,00 Drs. S.M. Wilting PA 3 0,75 Drs. T. Buffart PA 3 0,25 Ir. A.T. Hesselink PA 1 0,75 Drs. P. de Graaf RAD 3 0,20 Drs. R. Ljumanovic RAD 3 0,20 Drs. M. Vis REU 3 0,20 Ing. B.M. Klabbers RTH 1 0,40 Drs. J. van de Lande V&G 1 0,10 Drs. M. Verbruggen V&G 1 1,00 Total non tenured staff 15,74 Total research staff 28,04 Program 4: Therapy Dept WP Fte Full prof Prof.dr. W.W.A. Zuurmond ANES 1 0,20 Prof.dr. G.J. Ossenkoppele HEMA 1 0,50 Prof.dr. P.C. Huijgens HEMA 1 0,10 Prof.dr. E. Hack IG 1 0,28 Prof.dr. A.J.P. Veerman KG 1 0,40 Prof.dr. C.R. Leemans KNO 1 0,05 Prof.dr. H.F. Mahieu KNO 1 0,15 18

19 Prof.dr. W.P. Vandertop NCH 1 0,20 Prof.dr. J.J. Heimans NEU 1 0,20 Prof.dr. G.J. Teule NUCL/PET 1 0,07 Prof.dr. G. Giaccone ONC 1 0,50 Prof.dr. G.J. Peters ONC 1 0,80 Prof.dr. H.M. Pinedo ONC 1 0,30 Prof.dr. J. Lankelma ONC 1 0,80 Prof.dr. P.I.J.M. Wuisman ORTH 1 0,20 Prof.dr R.J. Scheper PA 1 0,30 Prof.dr. P. van der Valk PA 1 0,10 Prof.dr. B.A.C. Dijkmans REU 1 0,12 Prof.dr. B.J. Slotman RTH 1 0,20 Prof.dr. S. Senan RTH 1 0,20 Prof.dr. R.H.M. Verheijen V&G 1 0,05 Associated prof Dr. G.J. Schuurhuis HEMA 1 0,80 Dr. M.A. Cuesta HLK 1 0,05 Dr. G.J.L. Kaspers KG 4 0,40 Dr. J.M. Festen KNO 1 0,15 Dr. J. Huisman MPSY 1 p.m. Dr. C.J. van Groeningen ONC 1 0,50 Dr. E. Boven ONC 1 0,50 Dr. F.A.E. Kruyt ONC 1 0,80 Dr. K. Hoekman ONC 1 0,40 Dr. W.R. Gerritsen ONC 1 0,30 Dr. S. von Mensdorff-Pouilly V&G 1 0,50 Assistent prof Dr. M.E. Craanen GE 1 0,20 Dr. A.A. van den Loosdrecht HEMA 1 0,50 Dr. A.M. Dräger HEMA 1 0,30 Dr. Q. Waisfisz HEMA 1 0,60 Drs. J.J.W.M. Janssen HEMA 1 0,50 Dr. P.A.M. van Leeuwen HLK 1 0,35 Dr. M. van Vonderen IG 1 0,75 Dr. C.M. Zwaan KG 1 0,40 Dr. G. Kardos KG 1 0,18 Dr. M. van Furth KG 1 0,20 Dr. I.M. Verdonck de Leeuw KNO 4 0,40 Dr. R. de Bree KNO 1 0,20 Dr. M. Klein MPSY 1 0,40 Dr. C.M.F. Dirven NCH 1 0,30 Dr. J.C. Baaijen NCH 1 0,10 Dr. T.J. Postma NEU 1 0,30 Dr. A.A. Geldof NUCL/PET 1 0,50 Dr. J.C. Roos NUCL/PET 1 0,08 Dr. A.J.M. van den Eertwegh ONC 1 0,25 Dr. C.H. Smorenburg ONC 1 0,50 Dr. H.J. Broxterman ONC 3 1,00 Dr. A. Moll OOG 1 0,05 Dr. S. Imhoff OOG 1 0,10 Dr. E. Bloemena PA 1 0,10 19

20 Dr. A.E. Voskuyl REU 1 0,15 Dr. D. van Schaardenburg REU 1 0,20 Dr. W.F. Lems REU 1 0,17 Dr. A.H.S. Langendijk RTH 1 0,10 Dr. J. van Rijn RTH 1 0,60 Dr. M.V.M. Lafleur RTH 1 0,40 Dr. P. Sminia RTH 1 0,50 Dr. A.A. Geldof URO 1 0,50 Dr. A.A. Verstraeten V&G 1 0,20 Other tenured staff Drs. M.E.D. Chamuleau HEMA 1 0,50 Dr. D.P. Noske NCH 1 0,1 Drs. J. Zijlstra-Baalbergen NUCL/PET 1 0,30 Dr. C.H. van Denderen REU 1 Pm Dr. I. Bultink REU 1 Pm Drs. G. Jansen REU 1 0,40 Dr. B. van Triest RTH 1 Pm Dr. F.J. Lagerwaard RTH 1 p.m. Total tenured staff 22,50 Dept WI Fte Non tenured staff Dr. E. Dulmen- den Broeder KG 4 0,80 Dr. E.G. Haarman KG 1 0,10 Dr. J.H. Hooijberg KG 3 0,35 Drs. C.J.M. Broers KG 1 0,20 Drs. I. Koomen KG 1 0,20 Drs. C.D.L. van Gogh KNO 2 0,85 Dr. M.L.M. Lamfers NCH/Onc 2 1,00 Dr. E. Schagen ONC 3 1,00 Dr. G.S.A.T. van Rossum ONC 4 1,00 Dr. J. Carette ONC 3 1,00 Dr. J. Rodriguez ONC 2 1,00 Dr. M.C.A. Duyndam ONC 2 0,42 Dr. R. Fijneman ONC 4 0,08 Dr. R. Honeywell ONC 1 1,00 Dr. T. de Gruijl ONC 2 1,00 Dr. V. van Beusechem ONC 2 1,00 Dr. S.J.C. Stevens PA 4 0,30 Dr. T.G.M. Lauterslager PA 3 0,30 Dr. G.K. Kuipers RTH 4 0,70 PhD students Drs. K. Lammers GE 1 0,37 Drs. C.J. Hess HEMA 3 0,75 Drs. I. Houtenbos HEMA 1 0,75 Drs. A. van Rhenen HEMA 4 0,75 Drs. B. Molenkamp HLK 3 1,00 Drs. G. Melis HLK 3 1,00 Drs. A.I. Buizer KG 3 0,80 Drs. B.F. Goemans KG 4 0,25 Drs. I. Hubeek KG 4 0,75 20

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2006 VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2006 Address

More information

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2007 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University

More information

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI

VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology CCA/V-ICI Annual Report 2008 Address VUmc Cancer Center Amsterdam / VUmc Institute for Cancer & Immunology (CCA/V-ICI) VU University

More information

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors. Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins

More information

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING S FOR PHARMACY ONLINE CLAIMS PROCESSING The following is a list of error and warning codes that may appear when processing claims on the online system. The error codes are bolded. CODE AA AB AI AR CB CD

More information

1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ).

1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ). PROCEDIMIENTO DE RECUPERACION Y COPIAS DE SEGURIDAD DEL CORTAFUEGOS LINUX P ar a p od e r re c u p e ra r nu e s t r o c o rt a f u e go s an t e un d es a s t r e ( r ot u r a d e l di s c o o d e l a

More information

A disease and antibody biology approach to antibody drug discovery

A disease and antibody biology approach to antibody drug discovery A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!

More information

VIRUSES AND CANCER. Michael Lea

VIRUSES AND CANCER. Michael Lea VIRUSES AND CANCER 2012 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important

More information

DATING YOUR GUILD 1952-1960

DATING YOUR GUILD 1952-1960 DATING YOUR GUILD 1952-1960 YEAR APPROXIMATE LAST SERIAL NUMBER PRODUCED 1953 1000-1500 1954 1500-2200 1955 2200-3000 1956 3000-4000 1957 4000-5700 1958 5700-8300 1959 12035 1960-1969 This chart displays

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

USI Master Policy Information

USI Master Policy Information Policy I.D. Gender A.B. (#327) M 86 United of Omaha $ 1,000,000.00 A.B. (#430) - (#436) M 86 Metlife $ 2,000,000.00 A.G. #1 (#371), (#610), (#624) M Conseco Life $ 3,125,000.00 10/Apr/10 A.G. #2 (#380),

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Activation and effector functions of HMI

Activation and effector functions of HMI Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ

More information

Rheumatoid arthritis: an overview. Christine Pham MD

Rheumatoid arthritis: an overview. Christine Pham MD Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching

More information

Fulfilling the Promise

Fulfilling the Promise Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,

More information

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System 1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

False positive PET in lymphoma

False positive PET in lymphoma False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)

More information

Recent Review Papers on Simian-Virus (SV-40), Asbestos and Mesothelioma. Bibliography

Recent Review Papers on Simian-Virus (SV-40), Asbestos and Mesothelioma. Bibliography Evans AS, Mueller NE (1990) Viruses and cancer causal associations. Ann Epidemiol 1(1): 71-92. Carbone M, Rizzo P & Pass HI (1995) Association of Simian Virus 40 with Rodent and Human Mesotheliomas. DNA

More information

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Development of Bone Metastases in Men With Prostate Cancer

Development of Bone Metastases in Men With Prostate Cancer Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant

More information

Chapter 17A: Adaptive Immunity Part I

Chapter 17A: Adaptive Immunity Part I Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

Drug Development Services

Drug Development Services Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Chapter 43: The Immune System

Chapter 43: The Immune System Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

More information

Future Trends in Airline Pricing, Yield. March 13, 2013

Future Trends in Airline Pricing, Yield. March 13, 2013 Future Trends in Airline Pricing, Yield Management, &AncillaryFees March 13, 2013 THE OPPORTUNITY IS NOW FOR CORPORATE TRAVEL MANAGEMENT BUT FIRST: YOU HAVE TO KNOCK DOWN BARRIERS! but it won t hurt much!

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia

Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425

More information

C o a t i a n P u b l i c D e b tm a n a g e m e n t a n d C h a l l e n g e s o f M a k e t D e v e l o p m e n t Z a g e bo 8 t h A p i l 2 0 1 1 h t t pdd w w wp i j fp h D p u b l i c2 d e b td S t

More information

Therapeutic Systems Immunology

Therapeutic Systems Immunology Therapeutic Systems Immunology Coordination: Robert Preissner, Charité, Berlin 13 Partners from Berlin (7) Göttingen (1) Heidelberg (1) Rostock (2) Tübingen (1) Overview Intro / Mission Partners Systems

More information

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Basics of Immunology

Basics of Immunology Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,

More information

Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org

Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org Selective IgA deficiency (slgad) hello@piduk.org 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

Medical Therapies Limited EGM Presentation

Medical Therapies Limited EGM Presentation Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for

More information

Shantaram S. Joshi, Ph.D.

Shantaram S. Joshi, Ph.D. Shantaram S. Joshi, Ph.D. Functional Genomics of Leukemia Dendritic Cell Based Therapy for Cancer Dept. of Genetics, Cell Biology and Anatomy University of Nebraska Medical Center Omaha, Nebraska 68198-6395

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

The Need for a PARP in vivo Pharmacodynamic Assay

The Need for a PARP in vivo Pharmacodynamic Assay The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235

More information

Microbiology AN INTRODUCTION EIGHTH EDITION

Microbiology AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein

More information

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D. The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against

More information

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system IMMUNOLOGY OF HIV INFECTION AND AIDS Interactions between HIV and the immune system Basic Statistics United States In the U.S. in 2010, 1.1 million people were living with HIV infection. About 50,000 people

More information

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University SYMPOSIUM June 15, 2013 Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Bette Korber Los Alamos National Labs HIV evolution and the neutralizing antibody response We have recently

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Corporate Medical Policy Genetic Testing for Fanconi Anemia

Corporate Medical Policy Genetic Testing for Fanconi Anemia Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2016 3/2017 3/2016 Description

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

Report from the visiting commitee

Report from the visiting commitee Section des Unités de recherche Report from the visiting commitee Research unit: Biothérapies hépatiques University of Nantes January 2008 Section des Unités de recherche Report from the visiting committee

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13

HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13 SECTION 13 HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES CONTACT INFORMATION Jason Cyster, PhD (Email) READING Basic Immunology: Functions and Disorders of the Immune System. Abbas,

More information

New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto

New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic

More information

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not

More information

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology INTRODUCTION 2009 A university wishing to have an accredited program in Pediatric Hematology/Oncology must also

More information

Immunology in pathology (immunopathology) Patology. immunology in pathology. immunologic response. lecture 3

Immunology in pathology (immunopathology) Patology. immunology in pathology. immunologic response. lecture 3 Patology Immunology in pathology (immunopathology) lecture 3 prof. dr hab. n. med. Andrzej Marszałek immunology in pathology Diseases with immunologic mechanism of tissue injury. Hypersensitivity reactions:

More information

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific

More information

Types of Hypersensitivity. Type I: Allergic Reactions. more on Allergic Reactions

Types of Hypersensitivity. Type I: Allergic Reactions. more on Allergic Reactions Chapter 19: Disorders of the Immune System 1. Hypersensitivity 2. Autoimmunity 3. Transplant Rejection 1. Hypersensitivity What is Hypersensitivity? Hypersensitivity is an immunological state in which

More information

A powerful model of endometrial carcinogenesis! molecular analysis and rational design of immunological intervention approaches

A powerful model of endometrial carcinogenesis! molecular analysis and rational design of immunological intervention approaches A powerful model of endometrial carcinogenesis! molecular analysis and rational design of immunological intervention approaches Afrouz Behboudi PhD, Associate Prof. School of Life Sciences, University

More information

Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga. Jorge S Reis-Filho, MD PhD FRCPath

Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga. Jorge S Reis-Filho, MD PhD FRCPath Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga Jorge S Reis-Filho, MD PhD FRCPath Summary How do PARP inhibitors work? Synthetic lethality Potential

More information

HR DEPARTMENTAL SUFFIX & ORGANIZATION CODES

HR DEPARTMENTAL SUFFIX & ORGANIZATION CODES HR DEPARTMENTAL SUFFIX & ORGANIZATION CODES Department Suffix Organization Academic Affairs and Dean of Faculty, VP AA 1100 Admissions (Undergraduate) AD 1330 Advanced Ceramics, Colorado Center for--ccac

More information

Figure 14.2 Overview of Innate and Adaptive Immunity

Figure 14.2 Overview of Innate and Adaptive Immunity I M M U N I T Y Innate (inborn) Immunity does not distinguish one pathogen from another Figure 14.2 Overview of Innate and Adaptive Immunity Our first line of defense includes physical and chemical barriers

More information

Earthquake Hazard Zones: The relative risk of damage to Canadian buildings

Earthquake Hazard Zones: The relative risk of damage to Canadian buildings Earthquake Hazard Zones: The relative risk of damage to Canadian buildings by Paul Kovacs Executive Director, Institute for Catastrophic Loss Reduction Adjunct Research Professor, Economics, Univ. of Western

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

1150 W. Medical Center Dr. Research Investigator Ann Arbor, MI 48109 Department of Microbiology and Immunology phone: (734)763-5364

1150 W. Medical Center Dr. Research Investigator Ann Arbor, MI 48109 Department of Microbiology and Immunology phone: (734)763-5364 Alteri, Christopher J. 5641 Medical Science Bldg. II 1150 W. Medical Center Dr. Research Investigator Ann Arbor, MI 48109 Department of Microbiology and Immunology phone: (734)763-5364 University of Michigan

More information

Name (print) Name (signature) Period. (Total 30 points)

Name (print) Name (signature) Period. (Total 30 points) AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

AN INTRODUCTION TO IMMUNOLOGY. Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital

AN INTRODUCTION TO IMMUNOLOGY. Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital AN INTRODUCTION TO IMMUNOLOGY Paul Thomas Unit 1 Department of Immunology St. Jude Children s Research Hospital CATEGORIES OF PATHOGENS Viruses (~0.2 microns) Bacteria (1-2 microns) Parasites (Millimeters)

More information

Microbiology 532 Immunology Examination KEY October 30, 2003

Microbiology 532 Immunology Examination KEY October 30, 2003 KEY October 30, 2003 All questions have equal point value. You may keep the test questions. Multiple Choice (choose the best answer) 1. Receptors associated with innate immunity recognize microbes by detecting:

More information

Lymphomas after organ transplantation

Lymphomas after organ transplantation Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

More information

American Cancer Society Extramural Grants

American Cancer Society Extramural Grants Page: 1 Graduate Scholarships in Cancer Nursing Practice (GSCNP) GSCNP-14-118-01 Abbott, Linda, MSN MENTOR: Hooke, Mary C., PhD, RN School of Nursing Graduate Scholarship in Cancer Nursing Practice 07/01/2014

More information

MAKE ANTIBODIES. Signs & Symptoms of Primary Immune Deficiency

MAKE ANTIBODIES. Signs & Symptoms of Primary Immune Deficiency Signs & Symptoms of Primary Immune Deficiency MAKE ANTIBODIES Dr Jovanka King Department of Allergy & Immunology Women s & Children s Hospital, Adelaide Overview Cook s tour of the immune system Signs

More information

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Nele Claes 1 *; Tessa Dhaeze 1 *; Judith Fraussen PhD 1 ; Bieke Broux

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function: Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic

More information

New HLA class I epitopes defined by murine monoclonal antibodies

New HLA class I epitopes defined by murine monoclonal antibodies Human Immunology 71 (2010) 456 461 Contents lists available at ScienceDirect New HLA class I epitopes defined by murine monoclonal antibodies Nadim El-Awar a, *, Paul I. Terasaki b, Anh Nguyen a, Mamie

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures

More information

Human Immunity. How our body s cells defend against microbial and viral invaders

Human Immunity. How our body s cells defend against microbial and viral invaders Human Immunity How our body s cells defend against microbial and viral invaders What is Immunity? The word immunity comes from the Latin immunus meaning free of burden. Thus; it is a body s general ability

More information

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic

More information

CANCER EXPLAINED. Union for International Cancer Control Union Internationale Contre le Cancer

CANCER EXPLAINED. Union for International Cancer Control Union Internationale Contre le Cancer MEDIA FACTSHEET CANCER EXPLAINED What is cancer? Cancer is a disease which occurs when changes in a group of normal cells within the body lead to uncontrolled growth causing a lump called a tumour; this

More information

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma Occult HBV Infection: Assessment and Clinical Significance D. Lorne Tyrrell Director, Li Ka Shing Institute of Virology University of Alberta

More information

An Introduction to Cancer and Basic Cancer Vocabulary

An Introduction to Cancer and Basic Cancer Vocabulary An Introduction to Cancer and Basic Cancer Vocabulary Marc B. Garnick, MD Beth Israel Deaconess Medical Center Harvard Medical School, Boston Medical Director Cancer Programs Northeast Hospital Corporation,

More information

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary

More information

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com

EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:

More information

3 Summary of clinical applications and limitations of measurements

3 Summary of clinical applications and limitations of measurements CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin 16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant

More information

Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor T Cell Therapy Chimeric Antigen Receptor T Cell Therapy Yi Lin, MD, PhD Mayo Clinic, Rochester, MN Alliance Spring Group Meeting - May 13, 2016 Presentation Objectives l Scientific overview of chimeric antigen receptor

More information

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

More information

SINPE trial, Ann Surg 2009. Overall morbidity. Minor Major. Infectious Non infectious. Post-hoc analysis WL < %5 (n=379) WL between 5-10% (n=49)

SINPE trial, Ann Surg 2009. Overall morbidity. Minor Major. Infectious Non infectious. Post-hoc analysis WL < %5 (n=379) WL between 5-10% (n=49) Chinese International Symposium on Nutritional Oncology Changchun, June 20-21 2014 IMMUNONUTRITION IN CANCER PATIENTS IMMUNONUTRITION IN SURGERY OBJECTIVE To get the patient undergoing major surgery for

More information

Chapter. CPT only copyright 2008 American Medical Association. All rights reserved. 9Ambulance

Chapter. CPT only copyright 2008 American Medical Association. All rights reserved. 9Ambulance Chapter 9Ambulance 9 9.1 Enrollment........................................................ 9-2 9.2 Emergency Ground Ambulance Transportation.............................. 9-2 9.2.1 Benefits, Limitations,

More information

Neoplasms. Review of Normal Cells. Bio 375 Pathophysiology

Neoplasms. Review of Normal Cells. Bio 375 Pathophysiology Neoplasms Bio 375 Pathophysiology Review of Normal Cells During its life span, each cell follows the basic cell cycle of growth and reproduction called mitosis The timing of each event varies with the

More information